ACUMEN PHARMACEUTICALS INC (ABOS) Stock Overview
NASDAQ:ABOS - US00509G2093 - Common Stock
ABOS Key Statistics, Chart & Performance
The current stock price of ABOS is 1.39 USD. In the past month the price decreased by -4.79%. In the past year, price decreased by -49.27%.
ABOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.65 | 367.55B | ||
| AMGN | AMGEN INC | 13.2 | 155.03B | ||
| GILD | GILEAD SCIENCES INC | 14.72 | 141.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.97 | 99.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.86 | 62.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.53B | ||
| ARGX | ARGENX SE - ADR | 76.37 | 43.33B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.06 | 35.68B | ||
| INSM | INSMED INC | N/A | 28.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.76B | ||
| NTRA | NATERA INC | N/A | 22.38B | ||
| BIIB | BIOGEN INC | 8.52 | 19.99B |
Related stock screener links
About ABOS
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
Company Info
ACUMEN PHARMACEUTICALS INC
427 Park St.
Charlottesville VIRGINIA US
CEO: Daniel O'Connell
Employees: 61
Phone: 19253688508
ACUMEN PHARMACEUTICALS INC / ABOS FAQ
What is the stock price of ACUMEN PHARMACEUTICALS INC today?
The current stock price of ABOS is 1.39 USD. The price decreased by -4.79% in the last trading session.
What is the ticker symbol for ACUMEN PHARMACEUTICALS INC stock?
The exchange symbol of ACUMEN PHARMACEUTICALS INC is ABOS and it is listed on the Nasdaq exchange.
On which exchange is ABOS stock listed?
ABOS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACUMEN PHARMACEUTICALS INC stock?
11 analysts have analysed ABOS and the average price target is 7.96 USD. This implies a price increase of 472.37% is expected in the next year compared to the current price of 1.39. Check the ACUMEN PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACUMEN PHARMACEUTICALS INC worth?
ACUMEN PHARMACEUTICALS INC (ABOS) has a market capitalization of 84.19M USD. This makes ABOS a Micro Cap stock.
How many employees does ACUMEN PHARMACEUTICALS INC have?
ACUMEN PHARMACEUTICALS INC (ABOS) currently has 61 employees.
What are the support and resistance levels for ACUMEN PHARMACEUTICALS INC (ABOS) stock?
ACUMEN PHARMACEUTICALS INC (ABOS) has a support level at 1.36 and a resistance level at 1.51. Check the full technical report for a detailed analysis of ABOS support and resistance levels.
Should I buy ACUMEN PHARMACEUTICALS INC (ABOS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABOS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABOS, evaluating the profitability, health, valuation and growth aspects
- ACUMEN PHARMACEUTICALS INC (ABOS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACUMEN PHARMACEUTICALS INC (ABOS) Sales and EPS estimates to see what analysts future expectations are.
- ACUMEN PHARMACEUTICALS INC (ABOS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACUMEN PHARMACEUTICALS INC (ABOS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACUMEN PHARMACEUTICALS INC (ABOS) Stock Chart to make your own analysis
- ACUMEN PHARMACEUTICALS INC (ABOS) Latest news and press-releases to stay up to date.
Does ACUMEN PHARMACEUTICALS INC (ABOS) stock pay dividends?
ABOS does not pay a dividend.
When does ACUMEN PHARMACEUTICALS INC (ABOS) report earnings?
ACUMEN PHARMACEUTICALS INC (ABOS) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of ACUMEN PHARMACEUTICALS INC (ABOS)?
ACUMEN PHARMACEUTICALS INC (ABOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.28).
What is the Short Interest ratio of ACUMEN PHARMACEUTICALS INC (ABOS) stock?
The outstanding short interest for ACUMEN PHARMACEUTICALS INC (ABOS) is 2.62% of its float. Check the ownership tab for more information on the ABOS short interest.
ABOS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ABOS. When comparing the yearly performance of all stocks, ABOS is a bad performer in the overall market: 80.7% of all stocks are doing better.
ABOS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABOS. ABOS may be in some trouble as it scores bad on both profitability and health.
ABOS Financial Highlights
Over the last trailing twelve months ABOS reported a non-GAAP Earnings per Share(EPS) of -2.28. The EPS decreased by -105.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.5% | ||
| ROE | -116.73% | ||
| Debt/Equity | 0.26 |
ABOS Forecast & Estimates
11 analysts have analysed ABOS and the average price target is 7.96 USD. This implies a price increase of 472.37% is expected in the next year compared to the current price of 1.39.